NCT06101927View on ClinicalTrials.gov

Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

May 31, 2024

Study Completion Date

December 30, 2024

Conditions
Prostate Cancer
Interventions
DRUG

Whole body study and SPECT with [99mTc]Tc-BQ0413

One single intravenous injection of \[99mTc\]Tc-BQ0413, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

Trial Locations (1)

Unknown

TomskNRMC, Tomsk

All Listed Sponsors
collaborator

Uppsala University

OTHER

lead

Tomsk National Research Medical Center of the Russian Academy of Sciences

OTHER

NCT06101927 - Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413 | Biotech Hunter | Biotech Hunter